NASDAQ:EVGN - Evogene Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$2.91 +0.01 (+0.34 %)
(As of 05/21/2018 01:33 AM ET)
Previous Close$2.91
Today's Range$2.86 - $2.91
52-Week Range$2.66 - $5.74
Volume3,014 shs
Average Volume4,095 shs
Market Capitalization$74.94 million
P/E RatioN/A
Dividend YieldN/A
Beta0.76

About Evogene (NASDAQ:EVGN)

Evogene logoEvogene Ltd., a biotechnology company, focuses on the enhancement of crop productivity and performance in the United States and Germany. It operates through two segments, Evogene and Evofuel. The Evogene segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. This segment develops seed traits enhancing plant yield and tolerance to abiotic stresses, such as enhanced tolerance to drought, heat, and salinity, as well as seed traits for enhancing plant resistance to biotic stresses, including resistance to diseases, pests, and insects; novel herbicides; and bio-stimulants, which include microbial-based products that are applied externally to the plant for yield enhancement. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Evofuel segment develops enhanced species of the castor bean plant to serve as a source of feedstock for biofuel and other industrial uses. The company has strategic collaborations with various agricultural companies, including BASF, Bayer, DuPont, Monsanto, and Syngenta that cover 24 products in various stages of development. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.

Receive EVGN News and Ratings via Email

Sign-up to receive the latest news and ratings for EVGN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Agricultural chemicals
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EVGN
CUSIPN/A
Phone972-8931-1900

Debt

Debt-to-Equity RatioN/A
Current Ratio15.62
Quick Ratio15.62

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$3.38 million
Price / Sales22.17
Cash FlowN/A
Price / CashN/A
Book Value$2.69 per share
Price / Book1.08

Profitability

EPS (Most Recent Fiscal Year)($0.81)
Net Income$-20,830,000.00
Net Margins-616.33%
Return on Equity-27.15%
Return on Assets-24.51%

Miscellaneous

Employees240
Outstanding Shares25,750,000

Evogene (NASDAQ:EVGN) Frequently Asked Questions

What is Evogene's stock symbol?

Evogene trades on the NASDAQ under the ticker symbol "EVGN."

How were Evogene's earnings last quarter?

Evogene (NASDAQ:EVGN) posted its earnings results on Wednesday, February, 28th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.21) by $0.03. The biotechnology company earned $0.73 million during the quarter. Evogene had a negative return on equity of 27.15% and a negative net margin of 616.33%. View Evogene's Earnings History.

When is Evogene's next earnings date?

Evogene is scheduled to release their next quarterly earnings announcement on Tuesday, May, 29th 2018. View Earnings Estimates for Evogene.

Who are some of Evogene's key competitors?

Who are Evogene's key executives?

Evogene's management team includes the folowing people:
  • Mr. Ofer Haviv CPA, CEO & Pres (Age 52)
  • Mr. Ido Dor, Exec. VP & GM of Ag-Biologicals (Age 42)
  • Mr. Eran Kosover, Exec. VP & GM of Ag-Chemicals (Age 41)
  • Mr. Alex Taskar, Chief Financial Officer (Age 52)
  • Dr. Hagai Karchi, Chief Technology Officer (Age 56)

Has Evogene been receiving favorable news coverage?

News articles about EVGN stock have been trending somewhat positive recently, Accern reports. The research firm rates the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Evogene earned a media sentiment score of 0.10 on Accern's scale. They also gave media stories about the biotechnology company an impact score of 46.39 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term.

Who are Evogene's major shareholders?

Evogene's stock is owned by many different of institutional and retail investors. Top institutional shareholders include ETF Managers Group LLC (0.14%). View Institutional Ownership Trends for Evogene.

Which major investors are buying Evogene stock?

EVGN stock was acquired by a variety of institutional investors in the last quarter, including ETF Managers Group LLC. View Insider Buying and Selling for Evogene.

How do I buy shares of Evogene?

Shares of EVGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Evogene's stock price today?

One share of EVGN stock can currently be purchased for approximately $2.91.

How big of a company is Evogene?

Evogene has a market capitalization of $74.94 million and generates $3.38 million in revenue each year. The biotechnology company earns $-20,830,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis. Evogene employs 240 workers across the globe.

How can I contact Evogene?

Evogene's mailing address is 13 GAD FEINSTEIN STREET, REHOVOT L3, 7612002. The biotechnology company can be reached via phone at 972-8931-1900 or via email at [email protected]


MarketBeat Community Rating for Evogene (EVGN)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  76 (Vote Outperform)
Underperform Votes:  85 (Vote Underperform)
Total Votes:  161
MarketBeat's community ratings are surveys of what our community members think about Evogene and other stocks. Vote "Outperform" if you believe EVGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EVGN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Evogene (NASDAQ:EVGN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AN/AN/AN/A
Consensus Rating Score: N/AN/AN/AN/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

Evogene (NASDAQ:EVGN) Consensus Price Target History

Price Target History for Evogene (NASDAQ:EVGN)

Evogene (NASDAQ:EVGN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/17/2016Credit Suisse GroupLower Price TargetOutperform$19.00 ➝ $10.00N/AView Rating Details
(Data available from 5/21/2016 forward)

Earnings

Evogene (NASDAQ:EVGN) Earnings History and Estimates Chart

Earnings by Quarter for Evogene (NASDAQ:EVGN)

Evogene (NASDAQ EVGN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/29/2018N/AView Earnings Details
2/28/2018n/a($0.21)($0.24)$0.73 millionViewListenView Earnings Details
11/22/2017Q3 2017($0.19)($0.20)$0.75 millionViewN/AView Earnings Details
8/10/20176/30/2017($0.13)($0.18)$1.18 millionViewN/AView Earnings Details
5/17/20173/31/2017($0.18)($0.19)$0.72 millionViewN/AView Earnings Details
2/27/2017Q4($0.18)($0.26)$1.18 millionViewListenView Earnings Details
11/21/2016Q3($0.07)($0.20)$1.54 millionViewN/AView Earnings Details
8/11/2016Q2($0.11)($0.18)$5.36 million$3.82 millionViewListenView Earnings Details
5/19/2016Q1($0.11)($0.13)$2.70 million$2.00 millionViewListenView Earnings Details
3/1/2016Q415($0.17)($0.22)$3.90 million$2.46 millionViewN/AView Earnings Details
11/18/2015Q315($0.15)($0.13)$3.50 million$3.31 millionViewListenView Earnings Details
8/5/2015Q215($0.19)($0.20)$4.40 million$2.66 millionViewN/AView Earnings Details
5/19/2015Q115($0.20)($0.13)$3.65 million$2.70 millionViewListenView Earnings Details
2/26/2015Q4($0.12)($0.19)$3.64 millionViewN/AView Earnings Details
11/10/2014Q314($0.10)($0.17)$4.20 million$3.16 millionViewN/AView Earnings Details
8/20/2014Q214($0.11)($0.13)$4.77 million$3.85 millionViewN/AView Earnings Details
5/7/2014Q1 14($0.13)($0.09)$5.40 million$3.86 millionViewN/AView Earnings Details
3/19/2014Q413($0.08)($0.20)$4.95 million$4.41 millionViewN/AView Earnings Details
10/24/2013Q3 2013($0.06)$4.23 millionViewN/AView Earnings Details
8/18/2013Q2 2013($0.05)$4.32 millionViewN/AView Earnings Details
5/13/2013Q1 2013($0.01)$4.62 millionViewN/AView Earnings Details
11/19/2012Q3 2012($0.03)ViewN/AView Earnings Details
8/13/2012Q2 2012($0.03)ViewN/AView Earnings Details
5/14/2012Q1 2012$0.01ViewN/AView Earnings Details
3/19/2012Q4 2011$0.09ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Evogene (NASDAQ:EVGN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Evogene (NASDAQ EVGN) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 35.34%
Insider Trading History for Evogene (NASDAQ:EVGN)
Institutional Ownership by Quarter for Evogene (NASDAQ:EVGN)

Evogene (NASDAQ EVGN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Evogene (NASDAQ EVGN) News Headlines

Source:
DateHeadline
Biomica Announces Participation in the Microbiome Invest Conference in London May 23, 2018Biomica Announces Participation in the Microbiome Invest Conference in London May 23, 2018
finance.yahoo.com - May 14 at 10:02 AM
Evogene Financial Results for the First Quarter of 2018 Earnings Announcement ScheduleEvogene Financial Results for the First Quarter of 2018 Earnings Announcement Schedule
finance.yahoo.com - May 10 at 9:30 AM
BRIEF-Evogene And Marrone Bio Innovations Announce Phase Advancement In Their Insect Control CollaborationBRIEF-Evogene And Marrone Bio Innovations Announce Phase Advancement In Their Insect Control Collaboration
www.reuters.com - May 8 at 9:13 AM
Financial Comparison: Terra Nitrogen (TNH) & Evogene (EVGN)Financial Comparison: Terra Nitrogen (TNH) & Evogene (EVGN)
www.americanbankingnews.com - May 5 at 1:39 PM
Evogene (EVGN) Upgraded by ValuEngine to HoldEvogene (EVGN) Upgraded by ValuEngine to Hold
www.americanbankingnews.com - May 3 at 10:05 PM
Evogene (EVGN) and Its Peers Financial SurveyEvogene (EVGN) and Its Peers Financial Survey
www.americanbankingnews.com - April 28 at 11:17 AM
Comparing SenesTech (SNES) and Evogene (EVGN)Comparing SenesTech (SNES) and Evogene (EVGN)
www.americanbankingnews.com - April 24 at 8:08 AM
Evogene (EVGN) vs. Its Peers Critical ReviewEvogene (EVGN) vs. Its Peers Critical Review
www.americanbankingnews.com - April 24 at 1:18 AM
Comparing Evogene (EVGN) & Its CompetitorsComparing Evogene (EVGN) & Its Competitors
www.americanbankingnews.com - April 23 at 11:04 AM
Evogene (EVGN) and The Competition Financial ReviewEvogene (EVGN) and The Competition Financial Review
www.americanbankingnews.com - April 22 at 11:24 PM
Head-To-Head Contrast: Evogene (EVGN) vs. The CompetitionHead-To-Head Contrast: Evogene (EVGN) vs. The Competition
www.americanbankingnews.com - April 19 at 7:21 PM
Reviewing Evogene (EVGN) and Its PeersReviewing Evogene (EVGN) and Its Peers
www.americanbankingnews.com - April 14 at 11:23 PM
Comparing Evogene (EVGN) and The CompetitionComparing Evogene (EVGN) and The Competition
www.americanbankingnews.com - April 14 at 7:21 PM
Financial Survey: Evogene (EVGN) & Its CompetitorsFinancial Survey: Evogene (EVGN) & Its Competitors
www.americanbankingnews.com - April 11 at 7:23 PM
Evogene (EVGN) & Its Rivals Head to Head AnalysisEvogene (EVGN) & Its Rivals Head to Head Analysis
www.americanbankingnews.com - April 10 at 7:09 PM
Evogene Files Annual Report for the Year Ended December 31, 2017Evogene Files Annual Report for the Year Ended December 31, 2017
finance.yahoo.com - April 9 at 9:31 AM
Evogene (EVGN) versus Its Competitors Head-To-Head ComparisonEvogene (EVGN) versus Its Competitors Head-To-Head Comparison
www.americanbankingnews.com - April 8 at 3:13 PM
Financial Analysis: Evogene (EVGN) versus The CompetitionFinancial Analysis: Evogene (EVGN) versus The Competition
www.americanbankingnews.com - April 6 at 9:02 AM
SenesTech (SNES) and Evogene (EVGN) Head-To-Head ReviewSenesTech (SNES) and Evogene (EVGN) Head-To-Head Review
www.americanbankingnews.com - April 5 at 3:04 PM
Evogene (EVGN) and The Competition Financial ComparisonEvogene (EVGN) and The Competition Financial Comparison
www.americanbankingnews.com - April 1 at 9:20 PM
Evogene Files Annual Report for the Year Ended...Evogene Files Annual Report for the Year Ended...
www.benzinga.com - April 1 at 5:02 PM
Zacks: Evogene Ltd (EVGN) Given $8.00 Average Price Target by BrokeragesZacks: Evogene Ltd (EVGN) Given $8.00 Average Price Target by Brokerages
www.americanbankingnews.com - March 19 at 11:36 PM
Evogene (EVGN) Downgraded to Strong Sell at ValuEngineEvogene (EVGN) Downgraded to Strong Sell at ValuEngine
www.americanbankingnews.com - March 3 at 6:06 PM
Zacks: Brokerages Set $8.00 Target Price for Evogene Ltd (EVGN)Zacks: Brokerages Set $8.00 Target Price for Evogene Ltd (EVGN)
www.americanbankingnews.com - March 3 at 1:12 AM
Evogene Ltd to Host Earnings CallEvogene Ltd to Host Earnings Call
finance.yahoo.com - February 28 at 5:08 PM
Evogene (EVGN) Posts Quarterly  Earnings Results, Misses Expectations By $0.03 EPSEvogene (EVGN) Posts Quarterly Earnings Results, Misses Expectations By $0.03 EPS
www.americanbankingnews.com - February 28 at 12:36 PM
Evogene Announces Positive Results in its Novel Mode-of-Action Herbicide ProgramEvogene Announces Positive Results in its Novel Mode-of-Action Herbicide Program
finance.yahoo.com - February 27 at 9:19 AM
Evogene (EVGN) Scheduled to Post Earnings on WednesdayEvogene (EVGN) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - February 21 at 4:46 AM
-$0.18 Earnings Per Share Expected for Evogene Ltd (EVGN) This Quarter-$0.18 Earnings Per Share Expected for Evogene Ltd (EVGN) This Quarter
www.americanbankingnews.com - February 17 at 3:20 PM
Evogene Financial Results for the Fourth Quarter and Full Year 2017 Earnings Announcement ScheduleEvogene Financial Results for the Fourth Quarter and Full Year 2017 Earnings Announcement Schedule
finance.yahoo.com - February 12 at 9:11 AM
Zacks: Brokerages Anticipate Evogene Ltd. (EVGN) to Post -$0.18 Earnings Per ShareZacks: Brokerages Anticipate Evogene Ltd. (EVGN) to Post -$0.18 Earnings Per Share
www.americanbankingnews.com - January 31 at 3:12 PM
Evogene to Participate in Israeli Consortium to Develop Phenotyping Tools and Systems for Precision AgricultureEvogene to Participate in Israeli Consortium to Develop Phenotyping Tools and Systems for Precision Agriculture
finance.yahoo.com - January 29 at 9:22 AM
Zacks: Brokerages Set $8.00 Price Target for Evogene Ltd. (EVGN)Zacks: Brokerages Set $8.00 Price Target for Evogene Ltd. (EVGN)
www.americanbankingnews.com - January 22 at 3:14 PM
Evogene Announces Positive 2nd Year Field Trial Results in Corn Bio-Stimulant Ag-Biologicals ProgramEvogene Announces Positive 2nd Year Field Trial Results in Corn Bio-Stimulant Ag-Biologicals Program
finance.yahoo.com - January 19 at 10:46 AM
-$0.18 EPS Expected for Evogene Ltd. (EVGN) This Quarter-$0.18 EPS Expected for Evogene Ltd. (EVGN) This Quarter
www.americanbankingnews.com - January 14 at 5:32 PM
 Brokerages Set $8.00 Target Price for Evogene Ltd. (EVGN) Brokerages Set $8.00 Target Price for Evogene Ltd. (EVGN)
www.americanbankingnews.com - January 6 at 11:52 AM
ETFs with exposure to Evogene Ltd. : December 27, 2017ETFs with exposure to Evogene Ltd. : December 27, 2017
finance.yahoo.com - December 28 at 9:46 AM
Stocks- U.S. Futures Push Forward as Tax Bill Set for Final VoteStocks- U.S. Futures Push Forward as Tax Bill Set for Final Vote
finance.yahoo.com - December 20 at 9:40 AM
Zacks: Evogene Ltd. (EVGN) Given Consensus Recommendation of "Hold" by BrokeragesZacks: Evogene Ltd. (EVGN) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - December 13 at 9:18 PM
ETFs with exposure to Evogene Ltd. : December 13, 2017ETFs with exposure to Evogene Ltd. : December 13, 2017
finance.yahoo.com - December 13 at 5:22 PM
Head-To-Head Survey: Evogene (EVGN) vs. Calyxt (CLXT)Head-To-Head Survey: Evogene (EVGN) vs. Calyxt (CLXT)
www.americanbankingnews.com - December 13 at 11:16 AM
 Analysts Anticipate Evogene Ltd. (EVGN) to Post -$0.18 Earnings Per Share Analysts Anticipate Evogene Ltd. (EVGN) to Post -$0.18 Earnings Per Share
www.americanbankingnews.com - December 11 at 5:26 PM
Evogene (EVGN) versus Calyxt (CLXT) Critical ComparisonEvogene (EVGN) versus Calyxt (CLXT) Critical Comparison
www.americanbankingnews.com - December 10 at 3:26 AM
Calyxt (CLXT) vs. Evogene (EVGN) Head to Head ReviewCalyxt (CLXT) vs. Evogene (EVGN) Head to Head Review
www.americanbankingnews.com - December 9 at 6:24 PM
Critical Survey: Evogene (EVGN) & Calyxt (CLXT)Critical Survey: Evogene (EVGN) & Calyxt (CLXT)
www.americanbankingnews.com - December 9 at 5:28 PM
Calyxt (CLXT) vs. Evogene (EVGN) Head-To-Head ContrastCalyxt (CLXT) vs. Evogene (EVGN) Head-To-Head Contrast
www.americanbankingnews.com - December 5 at 3:32 AM
Evogene Ltd. :EVGN-US: Earnings Analysis: Q3, 2017 By the Numbers : December 1, 2017Evogene Ltd. :EVGN-US: Earnings Analysis: Q3, 2017 By the Numbers : December 1, 2017
finance.yahoo.com - December 1 at 4:59 PM
Analyzing Evogene (EVGN) and Calyxt (CLXT)Analyzing Evogene (EVGN) and Calyxt (CLXT)
www.americanbankingnews.com - November 30 at 8:06 AM
Zacks: Evogene Ltd. (EVGN) Given $8.00 Average Target Price by AnalystsZacks: Evogene Ltd. (EVGN) Given $8.00 Average Target Price by Analysts
www.americanbankingnews.com - November 28 at 7:56 AM
Evogene (EVGN) versus Calyxt (CLXT) Head to Head SurveyEvogene (EVGN) versus Calyxt (CLXT) Head to Head Survey
www.americanbankingnews.com - November 27 at 10:08 AM

SEC Filings

Evogene (NASDAQ:EVGN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Evogene (NASDAQ:EVGN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Evogene (NASDAQ EVGN) Stock Chart for Monday, May, 21, 2018

Loading chart…

This page was last updated on 5/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.